Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults (BRIO)

Overview

About this study

The purpose of this study is to critically examine biological, clinical, and behavioral modulators of progressive resistance training (PRT)-associated exercise response heterogeneity (ERH) in physical function and whole-body metabolism in older adults..

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Aged greater than or equal to 65 years
  • Sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity
  • At risk for mobility disability score of less than or equal to 10 on the SPPB
  • Willing to be randomized into HE or PRT
  • Willing to be transported or transport themselves to the clinical sites for the intervention and assessments

​​​​​​​Exclusion Criteria:

  • Unwillingness to provide informed consent
  • Significant weight loss or gain (7.5% of body weight) in past six months
  • Current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)
  • Clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the “normal limits’, that are deemed to be of concern for participation in the study by the study physician
  • Acute or terminal illness
  • Mini Mental State Exam (MMSE) <23
  • Myocardial infarction in the previous 6 months or other symptomatic coronary artery disease
  • New York Heart Association Class III or IV congestive heart failure
  • Serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (>3 mm) on ECG
  • Chronic obstructive pulmonary disease requiring oxygen therapy
  • Upper or lower extremity fracture in the previous 6 months
  • Uncontrolled hypertension (150/90 mm Hg)
  • Neuromuscular diseases and/or drugs which affect neuromuscular function
  • Current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy
  • Presence of significant liver or renal disease (eGFR < 45 mL/min)
  • Diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus
  • HbA1c > 7%
  • BMI <21 or >35 for men or >40 for women
  • Excessive alcohol intake (>14 alcoholic beverages per wk.)
  • Current tobacco use
  • Current participation in any interventional clinical trial
  • Current use of weight loss medications

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/16/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nathan LeBrasseur, Ph.D., M.S.

Contact us for the latest status

Contact information:

Amanda Tweed

(507) 255-6663

Tweed.Amanda@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20583571

Mayo Clinic Footer